



**REMARKS**

In response to the restriction requirement, Applicants provisionally elect without traverse the invention set forth in Group I, claims 1-23, 27 and 29, drawn to the compounds, compositions, process of preparing and method of use of the compounds of formula (I) where  $p = 1$  and  $q = 1$ . Tentative election of a single species within the elected group has been further required by the Examiner. In response thereto, Applicants elect 1-isopropyl-4-[1-(6-trifluoromethylpyridin-3-yl)-piperidine-4-carbonyl]-piperazine or a salt thereof as set forth in claim 22, which compound is shown in the application as the hydrochloride salt, in Example 96. Its structure is depicted in Example 96 as



The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,

  
Bonnie L. Deppenbrock  
Attorney for Applicant  
Registration No. 28,209

Date: 25 July 2008  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-1577  
Facsimile: 919-483-7988